Overview
U.S. cannabis operator's Q1 revenue fell 4% yr/yr to $287 mln, gross margin was 59%
Company posted positive net income of $2 mln and adjusted EPS of $0.10
Q1 results supported by lower operating expenses
Outlook
Company says rescheduling of medical marijuana enables new opportunities for DEA registration
Result Drivers
RETAIL SALES MIX - 92% of revenue came from retail sales
COST MANAGEMENT - Operating expenses fell 10% yr/yr, contributing to net income
NEW DISPENSARIES - Opened three new dispensaries in Florida during the quarter
Company press release: ID:nPn9WS2rba
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$287 mln
Q1 Adjusted EPS
$0.10
Q1 EPS
$0.02
Q1 Adjusted Net Income
$20 mln
Q1 Net Income
$2 mln
Q1 Adjusted EBITDA
$100 mln
Q1 Gross Margin
59.00%
Q1 Gross Profit
$170 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Trulieve Cannabis Corp is C$19.00, about 39.4% above its May 6 closing price of C$13.63
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)